Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors

Published:2007-12 Issue: Volume:8 Page:S22-S34
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Brufsky Adam M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference71 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J Clin,2006

2. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane;Gonnelli;Bone,2007

3. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004;Winer;J Clin Oncol,2005

4. Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98;Coates;J Clin Oncol,2007

5. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial;Coombes;Lancet,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS;Biomedicines;2024-08-01

2. Link between estrogen deficiency osteoporosis and susceptibility to bone metastases: A way towards precision medicine in cancer patients;The Breast;2018-10

3. Body composition and bone mineral density in breast cancer survivors and non-cancer controls: A 12- to 15-month follow-up;European Journal of Cancer Care;2018-01-24

4. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer;Breast Cancer Research;2017-08-09

5. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial;Bone;2016-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3